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Duchenne muscular dystrophy is a muscle disease caused by mutation in the gene that encodes the cytoskeletal protein 
dystrophin. It is inherited in an X-linked recessive fashion. A number of therapies are continuously being developed to slow 
down the progression of the disease and increase patients’ life expectancy. Steroid use in Duchenne muscular dystrophy is 
associated with a lower mortality rate (hazard ratio = 0.24; 95% CI = 0.07–0.91; p = 0.0351). Although recent studies have 
concluded that prolonged steroid use is associated with short stature and overweight, a meta-analysis of 12 studies has shown 
that steroids can increase strength, muscle function, and quality of life. Restoration of dystrophin gene expression is the basis 
of genetically engineered therapies. Potential therapies of this type include exon skipping, the use of recombinant adeno-
associated virus which delivers mini-dystrophin, and surrogate gene transfer. In their development, the common challenges 
are associated with the size of gene product and the origin of dystrophin gene expression. Stem cells are promising for future 
therapy. Regardless of the challenges and controversies associated with stem cells, several clinical trials show an increase 
of  muscle strength in patients who have received such therapies.
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Dystrofia mięśniowa Duchenne’a jest chorobą dziedziczoną w sposób recesywny, sprzężoną z chromosomem X, spowodowaną 
mutacjami w genie DMD kodującym białko dystrofinę. Obecnie opracowywane terapie mają na celu spowolnienie progresji 
choroby oraz przedłużenie przeżycia pacjentów. Leczenie z użyciem kortykosteroidów wiąże się z mniejszym ryzykiem zgonu 
(współczynnik ryzyka = 0,24; 95% CI = 0,07–0,91; p = 0,0351). Choć ostatnio prowadzone badania wykazały, że długotrwałe 
stosowanie kortykosteroidów przyczynia się do niskiego wzrostu i nadwagi, w metaanalizie 12 badań stwierdzono ich wpływ 
na zwiększenie siły mięśni, poprawę ich funkcji i lepszą jakość życia chorych. Odzyskanie ekspresji genu dystrofiny stanowi 
podstawę terapii genowych, w  tym metody pomijania zmutowanego egzonu (tzw. exon skipping), zastosowania 
rekombinowanych wirusów związanych z adenowirusami w celu wprowadzenia minidystrofiny oraz wymiany genu (gene 
transfer). Trudności związane z terapiami genowymi wiążą się z rozmiarem genu oraz pochodzeniem ekspresji dystrofiny. 
Inną obiecującą terapię stanowią komórki macierzyste. Bez względu na trudności i kontrowersje związane z leczeniem tego 
typu kilka badań klinicznych wykazało, że poprawia ono siłę mięśniową u osób z chorobą Duchenne’a.
Słowa kluczowe: dystrofia mięśniowa Duchenne’a, terapia, inżynieria genetyczna, komórki macierzyste
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INTRODUCTION
Duchenne muscular dystrophy (DMD) is a form of muscular dystrophy in children. Its prevalence in the general population is about 3:100,000 inhabit-
ants. The number of DMD in newborn males is recorded as 
1:3,500 (Amato and Brooke, 2012; Passamano et al., 2012). 
As stated by Mendell, infants are less frequently affected 
(1:3,802–1:6,291); this particularly concerns male infants 
(Wein et al., 2015).
DMD is caused by the mutation in the gene that preclude 
the synthesis of the dystrophin and is related to the gene 
on the X chromosome (locus Xp 21) (Amato and Brooke, 
2012; Angelini and Peterle, 2012; Beytía et al., 2012; Cirak 
et al., 2012). Dystrophin is one of the proteins connected to 
muscles and encoded by the dystrophin gene. This gene was 
identified in 1987 (Mitrpant et al., 2009), and is the largest 
gene discovered in humans as it accounts for approximately 
0.1% of the total human genome (Amato and Brooke, 2012; 
Beytía et al., 2012; Cirak et al., 2012).
DMD can cause disability, respiratory disorders, cardiac 
dysfunction, and may lead to mortality (Bendixen et al., 
2012; Passamano et al., 2012). Therapies, ranging from 
pharmacologic agents and genetic engineering to stem cells, 
are being developed for several reasons. These therapies are 
designed to improve clinical symptoms, slow down the pro-
gression of the disease, and increase patients’ life expec-
tancy. This article will provide an overview of DMD and 
some challenges linked with future therapies.
PATHOPHYSIOLOGY
A mutation of dystrophin synthesis is the basic pathophysi-
ology of DMD (Angelini and Peterle, 2012). The open read-
ing frame of the dystrophin gene may include deletions, 
duplications, point mutations, or other smaller rearrange-
ments (Cirak et al., 2012). Most deletions occur between 
exons 44 and 55. When these mutations cause interference 
in the reading frame of dystrophin (“out of frame-muta-
tion”), this dystrophin protein formation is truncated, 
resulting in no dystrophin production and the development 
of DMD (Beytía et al., 2012).
Dystrophin connects the actin cytoskeleton with the extra-
cellular matrix through dystrophin-associated protein 
complex (DAPC) (Consalvi et al., 2011; Johnson et al., 
2012). DAPC contains sub-complexes, namely sarcogly-
can sub-complex, syntrophin, nNOS (neuronal nitric 
oxide synthase) and dystrobrevins sub-complex, as well as 
β-dystroglycan and α-dystroglycans sub-complex (Cirak 
et al., 2012).
Dystrophin is located at the cytoplasmic side of the sarco-
lemma. It contributes to signal delivery (Cirak et al., 2012) 
and maintains structural integrity of the skeletal muscles 
and the heart (Moorwood et al., 2011). It transduces by 
the power of the contractile apparatus with the extracel-
lular matrix (Beytía et al., 2012), and functions as a shock 
absorber that protects the muscle fibres from necrosis asso-
ciated with muscle contraction (Beytía et al., 2012; Mitrpant 
et al., 2009).
In the absence of dystrophin, the entire DAPC is lost from 
the sarcolemma. Consequently, muscles are unable to with-
stand the stress of normal muscle contractions (Koo et al., 
2012; Moorwood et al., 2011). This damage leads to influx 
of extracellular calcium, followed by the activation of pro-
teases in the cell (Rosenkranz, 2004; Spurney, 2012). Next, 
a cascade of deleterious processes takes place (Beytía et al., 
2012; Consalvi et al., 2011). Protease activity induces myo-
cyte apoptosis, inflammation, and fibrosis (Rosenkranz, 
2004; Spurney, 2012), resulting in failure of regeneration 
and replacement of muscle fibres with fat and connective 
tissues (Koo et al., 2012; Moorwood et al., 2011).
The absence of dystrophin in the cardiac muscle increases 
intracellular calcium levels, leading to the activation of 
calpains, myocardial cell degeneration or apoptosis and 
fibrosis. Excessive fibrosis conduces cardiomyopathy. 
Cardiac function decline stimulates the renin–angiotensin 
system and releases angiotensin II (AT II). AT II increases 
the transforming growth factor-β (TGF-β) expressions 
(particularly TGF-β1) through the activation of angiotensin 
receptor type 1 in cardiac myocytes and fibroblasts. TGF-β 
induces cardiac fibroblast proliferation, deposition of extra-
cellular matrix proteins, and development of cardiomyocyte 
hypertrophy (Rosenkranz, 2004; Spurney, 2012).
In the brain, the absence of dystrophin results in the disrup-
tion of the synapse integrity and interneuron transmission. 
Cognitive impairment is suspected due to a decrease in glu-
cose metabolism in the cerebellum, i.e. the area associated 
with cognitive ability (Nardes et al., 2012).
CLINICAL SYMPTOMS
Patients appear normal at birth and begin to show signs of 
clumsiness at the age of 3–5 years (Mitrpant et al., 2009). 
The diagnosis is often made at the age of 4, when proxi-
mal muscle weakness is seen (Gowers’ sign). Patients expe-
rience difficulty in rising from the floor between the age 
of 7–9 years, followed by inability to walk by the age of 
13 years (Merlini et al., 2012). Scoliosis occurs after the 
patient loses the walking ability (Nardes et al., 2012).
Patients are in the plateau phase if they do not experi-
ence motor development any longer (ranging from the age 
of 4 to 8 years). Plateau phase is followed by declination 
phases which are characterised by the loss of motor skills, 
a decrease in physical endurance, and more frequent falls 
(Bushby et al., 2010).
Cardiac abnormalities are discovered after the age of 
10 years (Spurney, 2012). The severity and onset of cardio-
myopathy vary and are unrelated to the individual dystro-
phin gene mutation (Strehle and Straub, 2015). Respiratory 
muscles run into fibrosis, which results in respiratory insuf-
ficiency. Delay in language acquisition, cognitive impair-
ment, and mental retardation are also observed (Nardes 
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et al., 2012). Death occurs due to cardiac or respiratory 
failure (Passamano et al., 2012).
Clinical features and increased plasma creatinine kinase 
are important in establishing the diagnosis (Wein et al., 
2015). The values of plasma creatinine kinase generally 
exceed 1,000  IU/L and can reach 30,000  IU/L (Strehle 
and Straub, 2015). A muscle biopsy is indicated in patients 
without a detectable mutation. Molecular genetic testing 
has replaced the role of muscle biopsy in many diagnostic 
centres (Strehle and Straub, 2015).
STEROID AGENTS
Corticosteroids are the standard treatment (McAdam 
et  al., 2012). The mechanisms of action of corticoste-
roids are: (1) reduction of muscle necrosis and inflam-
mation; (2) modulation of cell response to inflammation; 
(3) increase in muscle regeneration and growth due to ana-
bolic effects; (4) reduction of the rate of muscle breakdown; 
(5) action as a direct transcriptional modifier to increase 
dystrophin expression in muscle fibres; and (6) increase 
in synergistic molecules (Angelini and Peterle, 2012). 
Corticosteroids can slow the decline in function and muscle 
strength, prolong independent ambulation, improve lung 
function, delay the onset of cardiomyopathy, and reduce the 
incidence of scoliosis (Beytía et al., 2012; McAdam et al., 
2012; Wilton and Fletcher, 2011). Corticosteroid therapy is 
associated with a lower mortality rate (hazard ratio = 0.24; 
95% CI = 0.07–0.91; p = 0.0351) and a lower incidence of 
cardiomyopathy (hazard ratio = 0.38; 95% CI = 0.16–0.90; 
p = 0.0270) (Schram et al., 2013).
Initiation of corticosteroid therapy is not recommended for 
patients whose motor skills are still developing, especially 
patients under the age of 2 years. Corticosteroid therapy 
should be started in the plateau phase. The requirements 
for scheduled national immunisation should be met before 
starting this therapy (Angelini and Peterle, 2012; Beytía 
et al., 2012; Bushby et al., 2010).
The most frequent adverse effect of corticosteroids is 
a reduction in the patient’s height and weight gain. Other 
adverse effects include cataracts, vertebral fractures, cushin-
goid facies, acne, hirsutism, arterial hypertension, behav-
iour disorders, delayed puberty, immunosuppression, and 
gastrointestinal problems (Beytía et al., 2012). Recent stud-
ies on the corticosteroid use in DMD have concluded that 
prolonged steroid use is associated with short stature and 
heavier weight (Lamb et al., 2016).
Prednisone dosage is 0.75 mg/kg/day (Amato and Brooke, 
2012; Beytía et al., 2012; Bushby et al., 2010; Moxley et al., 
2005). The effect is expected to end at least in 3 years 
(Amato and Brooke, 2012). Meta-analyses of 12 studies 
showed that 0.75 mg/kg/day prednisone or prednisolone in 
DMD improved muscle strength in 6 months and quality of 
life in 12 months (Matthews et al., 2016).
Def lazacort is  a  synthetic steroid (Amato and 
Brooke, 2012). It possesses anti-inflammatory and 
immunosuppressive properties (Angelini and Peterle, 2012). 
Deflazacort 0.9 mg/kg/day is equivalent to 0.75 mg/kg/day 
of prednisone (Angelini and Peterle, 2012; Beytía et al, 
2012; Moxley et al., 2005). This synthetic steroid has fewer 
side effects, but causes more cataracts than prednisone 
(Beytía et al., 2012; McAdam et al., 2012). Corticosteroids 
can be administered every other day, on the weekends in 
high doses and occasionally (Tab. 1).
GENETIC ENGINEERING
Restoration of gene expression addressed to the loss of gene 
product or protein defect is the foundation of gene replace-
ment therapy. Challenges of gene therapy derive from 
the size of gene product and/or origin of gene expression 
(Mitrpant et al., 2009).
Myostatin is a part of a protein that forms the TGF-β group 
which regulates muscle size. Myostatin inhibition can be 
a potential therapy (Beytía et al., 2012; Malerba et al., 2012; 
Wilton and Fletcher, 2011). Several ways to inhibit myo-
statin are: administering follistatin, a myostatin receptor 
blocker, and destructive exon skipping for the myostatin 
gene. Follistatin inhibits the TGF-β member during mus-
cle growth. The disturbance of myostatin signalling path-
way from excessive expression of follistatin-related gene 
(FLRG), a serum protein associated with growth and differ-
entiation factors (GDF), and myostatin propeptide, results 
in substantially improved muscle function and muscle mass 
in both normal and dystrophic tissue (Malerba et al., 2012; 
Wilton and Fletcher, 2011).
Utrophin (“ubiquitous dystrophin”) is an autosomal homo-
log of dystrophin. It binds to proteins in the protein com-
plex attached to dystrophins. Dystrophin and utrophin 
share 74% of features at the amino acid level and pos-
sess very similar domain structures (Lovering et al., 2005; 
Moorwood et al., 2011; Wilton and Fletcher, 2011). Nabu-
metone, a cyclooxygenase inhibitor, activates utrophin and 
has anti-inflammatory activity (Beytía et al., 2012; Moor-
wood et al., 2011).
Exon skipping is a potential therapy since the discovery of 
gene expression manipulation using antisense oligonucle-
otides (Hoffman et al., 2011; Wilton and Fletcher, 2011). 
Antisense oligonucleotides are designed to produce a tran-
scription messenger of ribonucleic acid (mRNA) that pro-
duces several levels of truncated but functional dystrophin 
(Koo et al., 2012; Lovering et al., 2005). Antisense oligonu-
cleotides are short nucleic acid sequences designed to selec-
tively bind to the mRNA sequences or specific pre-mRNA 
to inflict a small double-helical region on the target mRNA. 
Through binding with this region and forming double heli-
ces at the target location, the mutated exon will be skipped. 
In this process, another pre-mRNA is re-edited properly 
within the framework, despite its shorter size (Lovering 
et al., 2005). They also mediate exon skipping during the 
pre-mRNA process for the excision of the exons that carry 
the termination codons in DMD (Fletcher et al., 2012). 
Duchenne muscular dystrophy: overview and future challenges
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In the intra-exonic mutations (exons that are located within 
the frame shift), excision of two or more exons are required 
to maintain the reading frame (Adkin et al., 2012).
To date, three different clinical trials have used deoxy-
ribonucleic acid oligomers on phosphorothioate back-
bone (ODN), an analogue, such as RNA with 2’-O-mod-
ified bases on phosphorothioate backbone (2-OMeAO), 
and phosphorodiamidate morpholino oligomers (PMOs) 
(Wilton and Fletcher, 2011). PMOs give consistent exon 
skipping effects in in vivo mdx animal models and in 
human muscle (Koo et al., 2012). The strategy of combin-
ing the restoration of dystrophins and myostatin inhibi-
tion through dual exon skipping has been reported using 
2’-O-methyl-phosphorothioate RNA antisense oligonucle-
otides (Malerba et al., 2012).
Exon 51 is chosen as the target because, by contrast with 
other exons, skipping at this exon can correct the read-
ing frames in several patients (Mitrpant et al., 2009). Exon 
51 has a potential value to be applied in about 1 out of 
10 patients with DMD (Fletcher et al., 2012). The skipping 
process of dystrophin exon 51 in patients with relevant 
deletions repairs the open reading frames and induces the 
expression of dystrophin proteins after an intramuscular 
injection (Cirak et al., 2012).
Drisapersen is an antisense oligonucleotide that causes 
skipping of exon 51. Triple-blind randomised placebo-con-
trolled studies have revealed significant improvement of 
walking distance in patients receiving continuous subcu-
taneous drisapersen 6 mg/kg weekly. Eteplirsen is a mor-
pholino preparation that leads to removal of exon 51 dur-
ing the RNA splicing process (excision of introns and 
joining of exons). Studies in patients receiving 30 mg/kg 
and 50 mg/kg intravenous eteplirsen weekly showed an 
increasing production of dystrophin by 40–50% on biopsy 
and improvement of walking ability (Strehle and Straub, 
2015; Wein et al., 2015).
Recombinant adeno-associated virus vectors (rAAV) car-
rying a miniaturised functional dystrophin gene (mini-
dystrophin), have the potential to reduce the speed of mus-
cle failure or to repair it (Bowles et al., 2012). The transfer 
of mini-dystrophin expressed by AAV is characterised 
by low efficiency and triggering of an immune response 
(Lovering et al., 2005).
One alternative approach is through a  surrogate gene 
transfer, in which overexpression of a different protein 
allows for a functional correction of muscle pathologic 
abnormality or dysfunction. One of the examples is over-
expression of the α7-integrin gene. It encodes a protein 
that directly links the extracellular matrix to the actin 
cytoskeleton (Wein et al., 2015).
STEM CELLS
In the skeletal muscle, in addition to the satellite cell popu-
lations (myogenic mononuclear precursor cells), other pro-
genitor cell populations that hold myogenic potential are 
also observed. They include mesangioblasts, MDSCs (mus-
cle-derived stem cells), muscle-derived CD133+ progeni-
tors, mesenchymal stem cells, and PW1 interstitial cells 
(Koo et al., 2012; Meregalli et al., 2013). Dystrophin expres-
sion also occurs in non-ambulatory patients after endome-
trial regenerative cell therapy (Ichim et al., 2010).
Ideal stem cells used to treat DMD should fulfil several cri-
teria: be expandable in vitro without losing stem cell pro-
prieties; be immune-privileged; differentiate into muscle 













Less effective, but can be considered in the situation when 
administering daily doses causes side effects that cannot 
be overcome.
According to Merlini et al. (2012), this method gives prolonged 
results of motor function but cannot replace the lost motor 
function
Dosage adjustments should 









Lack of data to make comparisons with daily dosage. 
Can be considered as an alternative if there are problems with 
weight gain and behavioural change.
Escolar et al. (2011) concluded that prednisone given on weekends 
(dosage 10 mg/kg/week and divided in 2 days) has similar positive 
effects with prednisone given daily
Dosage adjustments should 
be made when side effects 
cannot be tolerated




0.6 mg/kg on the 
1–20 days and 
not given on the 
remaining days 
of the month
Less effective, but has fewer side effects.
Considered to have the least therapeutic effectiveness, but is 
thought as a regimen that can be tolerated before the stoppage 
of steroid therapy. Intermittent therapy is thought to provide 
a safer profile in terms of side effects.
According to a cohort study on deflazacort therapy, intermittence 
gives prolonged results in ambulated patients
Dosage adjustments should 
be made when side effects 
cannot be tolerated
Sources: Beytía et al., 2012; Bushby et al., 2010; Escolar et al., 2011; Merlini et al., 2012.
Tab. 1. Alternative strategies of corticosteroid administration
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that have already been lost; reconstitute the satellite cell 
pool with functional stem cells, and lead to the improve-
ment in muscle strength (Sienkiewicz et al., 2015).
Isolated stem cells can be transduced in vitro by retroviral 
or lentiviral vectors. Genetically modified cells or healthy 
foreign donor cells are developed ex vivo and injected sys-
temically into the target muscle. Transplantation of autolo-
gous gene stem cell modification has the advantage of pre-
venting side effects of immune response and cell rejection 
(Koo et al., 2012).
At present, mesenchymal stem cells are defined as unde-
veloped biological cells, capable of proliferation, cell 
renewal, and tissue repair (Mafi et al., 2011). Several clin-
ical trials have shown an increase in muscle strength that 
was functional in patients receiving stem cell therapy, 
which was also verified in electromyography (Hogrel et al., 
2013; Périé et al., 2014; Sharma et al., 2013, 2014; Sienkie-
wicz et al., 2015).
The therapeutic effect of mesenchymal stem cells is pre-
sumably not only gained through direct differentiation 
towards the injured tissue, but also through the produc-
tion of paracrine factors inhibiting apoptosis. Other effects 
include stimulating proliferation within endogenous cells, 
and/or activating stem cells housed in the injured tissue. 
Local intramuscular administration of mesenchymal stem 
cells is possible with the addition of chemotactic/chemo-
tropic support in the form of intravenous CD34 (Ichim 
et al., 2010).
At present, two approaches to cell transfer are carried out 
for the systemic transport from regenerative transplant cells 
to the skeletal muscle. They are also known as mesangio-
blast stem cell system and CD133+. The CD133+ cells can 
be isolated from peripheral blood or skeletal muscle tissue, 
and differentiate into muscle cells, haematopoietic cells and 
endothelial cells (Koo et al., 2012).
A myoblast is a muscle precursor cell that can prolifer-
ate and produce thousands of daughter cells. It can be 
obtained from biopsies and grown in vitro (Lovering 
et al., 2005). Intramuscular transplantation of these cells 
produces dystrophin-expressed muscle fibres at the level 
of 20–30% after more than 18 months of transplantation 
(Koo et al., 2012).
Limitation of the clinical efficacy of myoblast transfer ther-
apy is mainly due to poor cell survival post-transplantation 
(Koo et al., 2012; Vella et al., 2011). The challenges of intra-
muscular myoblast transfer are associated with cell migra-
tion, systemic transport to the entire body, administering 
hundreds of intramuscular injections, overcoming immu-
nological rejection, and high cost (Koo et al., 2012; Lover-
ing et al., 2005).
CONCLUSION
Various therapies have been developed in treating DMD. 
Corticosteroids, with all their benefits and side effects, 
have been the standard treatment. The potential genetically 
engineered therapies include exon skipping, use of recombi-
nant adeno-associated virus carrying mini-dystrophin, and 
surrogate gene transfer. The challenges encountered in the 
development of these therapies refer to the product gene 
size, origin of dystrophin gene expression, transport effec-
tiveness, and immunological rejection. Stem cell therapy is 
the latest, controversial form of treatment. Its challenges 
include transport, immunological rejection, and high cost.
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